Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Osemitamab by Transcenta for Metastatic Biliary Tract Cancer: Likelihood of Approval
Osemitamab is under clinical development by Transcenta and currently in Phase II for Metastatic Biliary Tract Cancer. According to GlobalData,...
Osemitamab by Transcenta for Metastatic Biliary Tract Cancer: Likelihood of Approval
Osemitamab is under clinical development by Transcenta and currently in Phase II for Metastatic Biliary Tract Cancer. According to GlobalData,...
TST-003 by Transcenta for Metastatic Colorectal Cancer: Likelihood of Approval
TST-003 is under clinical development by Transcenta and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...